Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239446 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4GPR119 | |
| SCHEMBL25154183 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4GPR119 | |
| SCHEMBL26116742 | 0.94 | GPR119 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4GPR119 | |
| SCHEMBL2881371 | 0.92 | GPR119 (0.55) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL2881367 | 0.92 | GPR119 (0.55) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL3784890 | 0.92 | GPR119 (0.55) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL16144654 | 0.91 | MEN1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4NR1H2 | |
| SCHEMBL14971262 | 0.90 | GPR119 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4GPR119 | |
| SCHEMBL24364944 | 0.90 | GPR119 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4GPR119 | |
| SCHEMBL26543757 | 0.90 | GPR119 (0.45) | GPR119NR1H2HPGDJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1255739-B1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | USP30, UCHL1, ADRM1 | CHRNB2 2313/4885CHRNB4 2851/4885CHRNA3 3162/4885 |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | CHRNB2 3372/4885CHRNB4 3776/4885CHRNA3 2972/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | CHRNB2 4585/4885CHRNB4 4690/4885CHRNA3 4836/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | CHRNB2 3399/4885CHRNB4 3777/4885CHRNA3 3054/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB2 3217/4885CHRNB4 3299/4885CHRNA3 2163/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CHRNB2 903/4885CHRNB4 1918/4885CHRNA3 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.